Superworth

Akebia Therapeutics price to book ratio AKBA

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026
6.3×
10-year median
3.2×
Against its 10-year history
66th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.8× to 42.4×
Peer median
1.6×

Akebia Therapeutics' price to book ratio is 6.3× as of Oct 23, 2026.

That is above its ten-year median of 3.2×, higher than on 66% of days in the last ten years.

Over that time it ranged from 0.8× in Oct 2022 to 42.4× in Jun 2025.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far6.3×6.3×13.7×
202510.6×9.8×42.4×
2024n/m a value too high to mean anything
202321.5×8.5×21.5×
20227.7×0.8×7.7×
20212.9×1.4×3.7×
20201.3×0.9×4.3×
20191.7×0.8×3.4×
20182.2×2.2×7.4×
20177.0×3.6×20.8×
20164.0×1.5×4.0×
20152.7×1.3×3.3×
20142.1×1.8×4.6×

Against its peers

Companies in Drug Manufacturers - General nearest Akebia Therapeutics' size, closest first, today.

CompanyPrice to book ratio
AKBAAkebia Therapeutics6.3×
NATRNatures Sunshine Products1.3×
LFVNLifevantage2.2×
SPROSpero Therapeutics1.5×
ARVNArvinas0.8×
ATNMActinium Pharmaceuticals1.6×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
Peer median1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Akebia Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.